NURIX THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN REGISTRATIONAL PHASE 3 DAYBREAK CLL-306 TRIAL OF BEXOBRUTIDEG IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Reuters · 08/04 05:00

Please log in to view news